Pharmaceuticals Expertise
Context and Challenges:
- Pfizer wanted to grow sales of its last-in-class breast cancer treatment Aromasin
- Little awareness that Aromasin was the only drug in its class shown to improve survival
- NICE about to pick only one of the drugs in this class for the UK formulary
Solution:
- Met with marketing & medical teams to review study data and competitive environment
- Created and conducted international media campaign on Aromasin’s unique benefit in class
Results:
- Media campaign key to 30% year-end sales growth, per Pfizer US Director of Marketing
- Aromasin selected for NICE formulary over competitors
Tags: aromasin, nhs, Pfizer
